CTOs on the Move

Symbria

www.symbria.com

 
At Symbria, we unite passion, insight, and performance to help senior-living and post-acute providers build sustainable success. We don`t make this commitment lightly, understanding full well how challenging this goal is to achieve in today`s demanding, highly competitive environment. Every service we provide – from therapy to pharmacy to wellness to benchmarking – is thoughtfully developed and conscientiously implemented to amplify your ability to effectively and cost-efficiently meet the needs of the residents and patients your community serves.
  • Number of Employees: 1K-10K
  • Annual Revenue: $100-250 Million
  • www.symbria.com
  • 28100 Torch Parkway
    Warrenville, IL USA 60555
  • Phone: 630.413.5800

Executives

Name Title Contact Details

Similar Companies

MedcomSoft

MedcomSoft Inc. (MedcomSoft) is a developer and distributor of software solutions to the healthcare industry in Canada and United States. The Company develops, markets, licenses and supports healthcare software solutions to the office-based or ambulatory

BENESIGHT

BENESIGHT is a Pueblo, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alere

Alere is committed to delivering high performance diagnostics that meet growing global demand for accurate, easy-to-use and cost-effective tests. The Alere i molecular platform, for example, delivers lab-quality results for Influenza A&B in less than 15 minutes.

La Mesa Healthcare Center

La Mesa Healthcare Center is a La Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.